{"id":"NCT00965484","sponsor":"Pfizer","briefTitle":"Genotropin Study Assessing Use of Injection Pen","officialTitle":"Multicenter, Open-Label Study Assessing Dyad (Subject And Caregiver) Perception Of Convenience And Preference Of The Newly Developed Mark VII Injection Pen","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10","primaryCompletion":"2010-01","completion":"2010-01","firstPosted":"2009-08-25","resultsPosted":"2010-12-23","lastUpdate":"2011-01-28"},"enrollment":136,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Growth Hormone Deficiency","Idiopathic Short Stature"],"interventions":[{"type":"DEVICE","name":"New Genotropin Pen","otherNames":[]}],"arms":[{"label":"Genotropin pen","type":"EXPERIMENTAL"}],"summary":"Assessment of Genotropin patient and caregiver (Dyad) perception of convenience and preference of Genotropin injection pen. Patients already on genotropin will be asked to use a genotropin pen for 2 months. Patient and caregiver will be asked to complete a questionnaire at baseline and 2 months.","primaryOutcome":{"measure":"Percentage of Dyads (Participant and Caregiver or Parent) Reporting no Difference or Easier to Use for New Genotropin Mark VII Injection Pen Compared to Pre-study Experience With the Genotropin PenÂ®","timeFrame":"2 months","effectByArm":[{"arm":"Genotropin / Genotropin Mark VII Pen","deltaMin":73.68,"sd":null}],"pValues":[]},"eligibility":{"minAge":"8 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":25,"countries":["United States"]},"refs":{"pmids":["21118739"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6281291&StudyName=Genotropin%20Study%20Assessing%20Use%20of%20Injection%20Pen"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":136},"commonTop":["Headache","Injection-site pain","Pyrexia","Upper respiratory tract infection","Injection-site hematoma"]}}